Search Press releases Keywords From To 27 Sep 2024 Transparency notification BlackRock, Inc. Read More 27 Sep 2024 UCB announces late-breaking two-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe hidradenitis suppurativa at EADV 2024 Read More 26 Sep 2024 Transparency notification BlackRock, Inc. Read More 25 Sep 2024 Transparency notification BlackRock, Inc. Read More 25 Sep 2024 UCB presents new 4-year data for BIMZELX[®]▼(bimekizumab) in moderate to severe plaque psoriasis at EADV 2024 Read More 24 Sep 2024 Transparency notification BlackRock, Inc. Read More Pagination First page Previous page Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
